Upper GI Bleed Management Guidelines

Initial Assessment and Risk Stratification

A Glasgow Blatchford score of 1 or less can identify patients at very low risk for rebleeding who may not require hospitalization 1, 2
For patients requiring hospitalization, the suggested hemoglobin threshold for blood transfusion is less than 80 g/L in patients without cardiovascular disease, with a higher threshold for those with cardiovascular disease 1
Risk factors for poor outcomes include poor overall health status, melena, fresh red blood in emesis or nasogastric aspirate, and elevated urea, creatinine, or serum aminotransferase levels 2

Endoscopy should be performed within 24 hours of presentation for most patients with upper GI bleeding 1
Combination endoscopic therapy (injection plus thermal coagulation) is superior to either treatment alone for achieving hemostasis 1, 2
Endoscopic clips are suggested as an effective option for hemostatic therapy 1, 3
TC-325 (hemostatic powder) is suggested as a temporizing therapy, but not as sole treatment, in patients with actively bleeding ulcers 1, 3

H2-receptor antagonists are not recommended in the management of acute upper GI bleeding due to their limited efficacy compared to proton pump inhibitors 4, 5
Somatostatin and octreotide are not recommended in the routine management of nonvariceal upper GI bleeding 4, 5
Patients with bleeding ulcers with high-risk stigmata who have had successful endoscopic therapy should receive high-dose proton pump inhibitor therapy (intravenous loading dose of 80 mg followed by continuous infusion of 8 mg/h) for 3 days 1, 3, 2
After the initial 3-day high-dose IV PPI therapy, continued oral PPI therapy is suggested twice daily through 14 days, then once daily for a duration that depends on the nature of the bleeding lesion 1, 3

Patients considered at low risk for rebleeding after endoscopy can be fed within 24 hours 6, 2
All patients with upper GI bleeding should be tested for Helicobacter pylori and receive eradication therapy if infection is present 6, 2
Testing for H. pylori during acute bleeding may have increased false-negative rates; confirmatory testing outside the acute context may be necessary 6, 2

Early surgical consultation may be particularly beneficial in patients at high risk for failed endoscopic retreatment 5

PPI therapy is suggested for patients with previous ulcer bleeding who require antiplatelet or anticoagulant therapy for cardiovascular prophylaxis 1, 3

The strongest and most recent evidence still supports high-dose PPI therapy for high-risk patients following successful endoscopic therapy 1, 3, 2

The American College of Gastroenterology recommends administering intravenous pantoprazole or omeprazole as an 80 mg bolus followed by 8 mg/hour continuous infusion for 72 hours, then transitioning to oral PPI twice daily for 14 days, for nonvariceal upper GI bleeding with high-risk stigmata after successful endoscopic therapy, with a Grade C recommendation for pre-endoscopy use 7, 8, 9
High-dose intravenous PPI should be started immediately upon presentation, even before endoscopy, to improve endoscopic stigmata appearance, with evidence showing a potential cost-effectiveness, despite one study showing no difference in mortality or rebleeding when given to unselected patients 7, 8, 9

For patients with high-risk stigmata who received successful endoscopic therapy, administer 80 mg IV bolus of omeprazole or pantoprazole, followed by 8 mg/hour continuous infusion for 72 hours, to reduce rebleeding rates, mortality, and need for surgery compared to placebo or H2-receptor antagonists 7, 8, 10
Meta-analyses confirm this is a class effect applicable to both omeprazole and pantoprazole, with guideline recommendations consistently supporting the high-dose regimen based on broader evidence from multiple trials 7, 8, 10

Testing all patients for H. pylori and providing eradication therapy if positive reduces ulcer recurrence and rebleeding rates, according to the American College of Gastroenterology 7